AGIO Agios Pharmaceuticals Inc.

Agios to Participate in March Investor Conferences

Agios to Participate in March Investor Conferences

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the following March investor conferences:

  • Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. ET; and
  • Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 12:00 p.m. ET.

Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at . Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios

Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at .

Investor & Media Contact

Jessica Rennekamp

Senior Director, Corporate Communications



EN
02/03/2023

Underlying

AGIOAgios Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agios Pharmaceuticals Inc.

 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and ...

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026$1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31, 20...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conf...

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights. The live webcast will be accessible on t...

January 26, 2026 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Outlines 2026 Strategic Priorities and Key Milestones to Acceler...

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to followCompany progressing early- and mid-stage pipeline in multiple high-value indicationsClear path to profitability through the company’s existing commercial presence in thalassemia and PK deficiency, with potential to achieve over $1 billion ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference ...

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 8:15 a.m. PST / 11:15 a.m. EST. The live webcast will be accessible on the Investors section of the company's website () under the “Ev...

January 5, 2026 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Ane...

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indication AQVESME expected to be available in late January 2026, following AQVESME REMS program implementationCompany will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m....

December 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch